2 July 2024
Chairman’s Statement Performance During the year the net asset value (‘NAV’) total return, with borrowings calculated at fair value, was +17.6%. The share price…
1 July 2024
1 July 2024 Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer Imfinzi also…
28 June 2024
Trading Statement PZ Cussons plc (“PZ Cussons” or the “Group”) announces that trading in the final quarter of the financial year, which ended on…
27 June 2024
Harworth Group plc (“Harworth” or “the Group”) £106.6 million land sale at Skelton Grange for development of a hyperscale datacentre Proceeds will support increased…
SEGRO ACQUIRES €222 MILLION OF LOGISTICS WAREHOUSES IN THE NETHERLANDS SEGRO plc (“SEGRO” or the “Group”) has acquired three fully leased, highly reversionary logistics warehouses…
James Latham plc (“James Latham” or “the Company”) Preliminary Results Chairman’s statement I am very pleased to report good trading results for the financial…
Halma plc (‘Halma’ or the ‘Group’) Acquisition Halma, the global group of life-saving technology companies, today announces that it has acquired G.F.E. – Global…
25 June 2024
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials…